Gabather

Gabather's mission is to develop transformative medicines for neuropsychiatric disorders by targeting the brain's major inhibitory system, the GABA-A receptor. The company has achieved key milestones with its lead candidate, GT-002, a pro-cognitive modulator that has demonstrated safety, tolerability, and excellent pharmacokinetics in Phase I trials. Its strategy centers on using a unique drug discovery engine and early human target engagement studies to accelerate the development of novel treatments for conditions like Alzheimer's disease, schizophrenia, and major depressive disorder.

A proprietary GABA-A receptor pharmacophore model used as a drug discovery engine to rationally design novel small molecule modulators aimed at selectively restoring the brain's excitatory/inhibitory balance.

Faces competition from other next-generation GABA-A modulator developers (e.g., Sage Therapeutics), large pharma with deep CNS pipelines, and generic drugs. Differentiation hinges on demonstrating superior pro-cognitive efficacy and a cleaner side-effect profile through selective receptor modulation.